Entropy Neurodynamics Limited (ASX:ENP)
Australia · Delayed Price · Currency is AUD 0.0320
0.00 (0.00%)
Oct 22, 2026, 12:00 PM AEDT
Entropy Neurodynamics Revenue
In the fiscal year ending June 30, 2026, Entropy Neurodynamics had annual revenue of 1.91M AUD with 20.53% growth. Entropy Neurodynamics had revenue of 1.91M in the half year ending June 30, 2026. That makes Entropy Neurodynamics the 43,144th largest company in the world by revenue and 924th in Australia.
Revenue
1.91M
Revenue Growth
+20.53%
P/S Ratio
27.42
Revenue / Employee
n/a
Employees
n/a
Market Cap
52.28M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2026 | 1.91M | 324.75K | 20.53% |
| Jun 30, 2025 | 1.58M | 254.43K | 19.17% |
| Jun 30, 2024 | 1.33M | - | - |
| Aug 31, 2023 | - | - | - |
| Aug 31, 2022 | - | - | - |
| Aug 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Botanix Pharmaceuticals | 33.80M |
| Immutep | 19.93M |
| Neurizon Therapeutics | 17.59M |
| Amplia Therapeutics | 4.79M |
| Neurotech International | 4.73M |
| Alterity Therapeutics | 3.61M |
| Arovella Therapeutics | 3.50M |
| Prescient Therapeutics | 3.45M |